Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer

OBJECTIVE: Anlotinib was the standard monotherapy for patients with previously treated small cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade combined with antiangiogenic targeted drugs have proved to play a synergistic action for cancer treatment clinically....

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Yan-Yan, Qiao, Yi-Peng, Cheng, Jian-De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722563/
https://www.ncbi.nlm.nih.gov/pubmed/35002304
http://dx.doi.org/10.2147/IJGM.S337316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722563/
https://www.ncbi.nlm.nih.gov/pubmed/35002304
http://dx.doi.org/10.2147/IJGM.S337316

Ejemplares similares